Lim Chetana, Saliba Faouzi, Salloum Chady, Azoulay Daniel
Department of Digestive, Hepato-Biliary and Pancreatic Surgery and Liver Transplantation, AP-HP Pitié-Salpêtrière Hospital, Paris, France; Research Unit, Université de Picardie-Jules Verne, UR UPJV 7518 SSPC, Amiens, France.
Hepato-Biliary Center, AP-HP Paul Brousse Hospital, Paris-Saclay University, INSERM Unit 1193, 94800 Villejuif, France.
HPB (Oxford). 2025 Apr;27(4):434-444. doi: 10.1016/j.hpb.2025.01.005. Epub 2025 Jan 10.
Liver cirrhosis accounts for more than 90 % of portal hypertension cases, and the other cases are due to noncirrhotic portal hypertension (NCPH). Variceal bleeding is the most life-threatening complication of portal hypertension and its primary treatment is medical according to the Baveno VII guidelines. This review discusses the evidence on surgical portal decompression for adult patients with NCPH secondary to chronic extrahepatic portal vein obstruction (EHPVO).
This is a scoping review of the evidence for the feasibility and effectiveness of surgical portal decompression in adults with NCPH secondary to EHPVO.
This scoping review yielded 17 studies, including a total of 110 patients. Patient age(s) ranged from 19 to 68 years, with the majority undergoing nonphysiological (i.e., portosystemic shunts) shunts (N = 84, 76.4 %), mostly for variceal bleeding refractory to medical and endoscopic treatments. Physiological shunts (i.e., Rex shunts) had a potential advantage over nonphysiological shunts in postoperative rebleeding (5 % vs. 10 %) and hepatic encephalopathy rates (0 % vs. 13 %). Conversely, nonphysiological shunts had a potential advantage over physiological shunts in postoperative shunt thrombosis (8 % vs. 22 %).
This scoping review reported that surgical portal decompression is feasible in adults with NCPH due to EHPVO with favorable outcomes and long-term patency.
肝硬化占门静脉高压病例的90%以上,其他病例则归因于非肝硬化性门静脉高压(NCPH)。静脉曲张破裂出血是门静脉高压最危及生命的并发症,根据巴韦诺VII指南,其主要治疗方法是药物治疗。本综述讨论了针对慢性肝外门静脉阻塞(EHPVO)继发的NCPH成年患者进行手术门静脉减压的证据。
这是一项关于EHPVO继发的NCPH成年患者手术门静脉减压的可行性和有效性证据的范围综述。
该范围综述纳入了17项研究,共110例患者。患者年龄在19至68岁之间,大多数接受非生理性(即门体分流)分流术(N = 84,76.4%),主要用于治疗对药物和内镜治疗无效的静脉曲张破裂出血。生理性分流术(即雷克斯分流术)在术后再出血率(5%对10%)和肝性脑病发生率(0%对13%)方面比非生理性分流术具有潜在优势。相反,非生理性分流术在术后分流血栓形成方面(8%对22%)比生理性分流术具有潜在优势。
该范围综述报告称,对于EHPVO继发的NCPH成年患者,手术门静脉减压是可行的,预后良好且长期通畅。